| Vol. 9.09 – 10 March, 2021 |
| |
|
|
| Using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, scientists report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants. [Nature Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators discovered that SARS-CoV-2 required the lysosomal protein TMEM106B to infect human cell lines and primary lung cells. [Nature Genetics] |
|
|
|
| The authors analyzed the magnitude and phenotype of the SARS-CoV-2-specific T cell response in 100 donors at six months following infection. [Nature Immunology] |
|
|
|
| Researchers showed that B.1.1.7 remained sensitive to neutralization, albeit at moderately reduced levels, by serum samples from convalescent individuals and recipients of an mRNA vaccine and a protein nanoparticle vaccine. [Cell Host & Microbe] |
|
|
|
| Scientists revealed the subgenome landscape of SARS-CoV-2 and its regulatory features, providing a molecular basis for understanding subgenome biogenesis and developing novel anti-viral strategies. [Molecular Cell] |
|
|
|
| Investigators identified nonsynonymous mutations in MHC-I-restricted CD8+ T cell epitopes after deep sequencing of 747 SARS-CoV-2 virus isolates. [Science Immunology] |
|
|
|
| The authors assessed prototypic S and receptor binding domain subunit vaccines in homologous or heterologous prime-boost regimens in mice and non-human primates. [Nature Communications] |
|
|
|
| Researchers showed a COVID-19 immune signature associated with severity by integrating single-cell RNA-seq analysis from blood samples and broncho-alveolar lavage fluids with clinical, immunological and functional ex vivo data. [Nature Communications] |
|
|
|
| In this study scientists evaluated neutralization of a series of mutated Spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 Spike pseudotype and individual mutations. [Cell Reports] |
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| The authors showed that headless hemagglutinin stabilized-stem immunogens presented on ferritin nanoparticles elicited broadly neutralizing antibody responses to diverse H1 and H3 viruses in non-human primates when delivered with a squalene-based oil-in-water emulsion adjuvant, AF03. [Science Translational Medicine] |
|
|
|
| Scientists demonstrated that the initial B cell interaction with the founder HIV envelope was important for the development of broadly neutralizing antibodies. [Cell Host & Microbe] |
|
|
|
| Group 2 innate lymphoid cells were shown to synthesize and release acetylcholine during parasitic nematode infection. [Science Immunology] |
|
|
|
| The authors identified that activated innate lymphoid cells (ILC2s) up-regulate choline acetyltransferase (ChAT)—the enzyme responsible for the biosynthesis of acetylcholine. [Science Immunology] |
|
|
|
| Scientists report that amino acid chirality balanced by bacteria-mammal cross-talk modulated intestinal B cell fate and immunoglobulin A production. [Science Advances] |
|
|
|
|
| The authors discuss the hepatotropism of SARS-CoV-2, including the differential expression of viral receptors on liver cell types. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Investigators review how the engineered viral proteins technique emerged during HIV-1 Env vaccine development and its subsequent wider application to other viral vaccines including SARS-CoV-2. [Cell Host & Microbe] |
|
|
|
| Scientists summarize what they have learned in the following areas: epidemiology, virology, and pathogenesis, diagnosis, use of artificial intelligence in assisting diagnosis, treatment, and vaccine development. [Signal Transduction and Targeted Therapy] |
|
|
|
|
| CEPI and VBI Vaccines, Inc. announced a partnership to develop VBI’s enveloped virus like particle vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant first identified in South Africa. [CEPI (BusinessWire, Inc)] |
|
|
|
| AbCellera announced that bamlanivimab 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company, and etesevimab 1400 mg together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. [AbCellera (BusinessWire, Inc)] |
|
|
|
|
| March 24 – 26, 2021 Virtual |
|
|
|
|
|
| Uni Tübingen- Tübingen, Germany |
|
|
|
| The University of British Columbia- Vancouver, British Columbia, Canada |
|
|
|
| University of California Merced – Merced, California, United States |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| NCCR AntiResist – Basel, Switzerland |
|
|
|
|